Alvin Wells is a Rheumatology/Immunology physician affiliated with American College of Rheumatology. OpenAlex indexes 66 publications with 2,157 citations (h-index 21).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
137 Crystal Beach Dr Ste 121
Destin, FL 325413573
Telephone
850-807-4388Provider last certified this registry record 28 Aug 2024.
Industry payments
54 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202595 payments$95,803openpaymentsdata.cms.gov ↗
- UCB, Inc.Program year202571 payments$39,148openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202540 payments$34,814openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
28.8%RANK Ligand Inhibitor19%Denosumab100%Part B, office-administered≥16 patientsNonsteroidal Anti-inflammatory Drug5%Diclofenac Sodium78%Nabumetone14%Naproxen8%Part D<11 patients+ 5 more classes in this area
Nervous system
24.4%Opioid Agonist7.6%Tramadol Hcl78%Oxycodone-Acetaminophen15%Oxycodone Hcl7%Part D<11 patientsGabapentinoids6.1%Gabapentin75%Pregabalin25%Part D≥47 patients+ 8 more classes in this area
Cancer & immunology
18.7%Folate Analog Metabolic Inhibitor4.3%Methotrexate100%Part D≥50 patientsTNF inhibitor3%Humira(Cf) Pen56%Enbrel Sureclick26%Humira(Cf)18%Part D<11 patients+ 8 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Understanding the immunopathophysiology of polymyalgia rheumatica: implications for treatment
Annals of the Rheumatic Diseases
2025 - Health Disparities in Rheumatology in the United States
Open Access Rheumatology Research and Reviews
2025
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”